ASAman Saini

Aman Saini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aman Saini has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neuropsychiatric Features of Individuals With LGI1-Antibody Encephalitis

    by Aman Saini, Eric Kelleher, Ella Burchill, Harry Costello, Eileen Joyce, Lorena Valdearenas, Robert Howard, Rachel Brown, Thomas Miller, Jonathan Rogers, et al.

  • Open Access

    Colorectal cancer survival in patients without curative measures: a retrospective cohort study

    by Aman Saini, Ademola Adeyeye, Hao Gao, Molly Steele, Alisha Jafri, Pranay Ruparelia, Bhavya Manchukonda, Amyn Haji

    Background: A substantial proportion of colorectal cancer (CRC) patients are managed without curative intent due to frailty, comorbidity, or patient choice. Outcomes in this heterogeneous population remain incompletely characterised. We evaluated survival and treatment patterns in patients managed non-curatively, including exploratory analyses by tumour sidedness and metastatic status. Methods: We conducted a retrospective cohort study of patients diagnosed with CRC at King’s College Hospital, London, between 2013 and 2022. Patients with histologically or radiologically confirmed CRC discussed at the multidisciplinary team (MDT) meeting were included; those receiving curative-intent treatment were excluded. Baseline variables included Eastern Cooperative Oncology Group (ECOG) performance status, tumour location, and metastatic disease at diagnosis. Overall survival (OS) from diagnosis was analysed using Kaplan-Meier methods and multivariable Cox regression. Results: Of 1,501 patients with CRC, 267 (18%) were managed non-curatively. Mean age was 74.7 years, and 60.3% were male; 59.9% were ECOG 0–2. Chemotherapy (28%) and surgery (15.7%) were the most frequent treatments. 5.2% required emergency surgery. Median OS was 210 days [95% confidence interval (CI): 205–210]. On multivariable analysis, ECOG ≥3 [hazard ratio (HR) 2.40, 95% CI: 1.42–4.05; P=0.001] and metastatic disease (HR 2.36, 95% CI: 1.41–3.94; P=0.001) were independently associated with worse OS. Tumour sidedness was not associated with survival (HR 1.00, 95% CI: 0.62–1.61; P=0.99). Conclusions: Patients with CRC managed non-curatively are often ambulant and may continue to receive supportive interventions aimed at maintaining quality of life. These findings support individualised risk stratification and prospective evaluation incorporating frailty and quality-of-life measures.

  • Current concepts in portal vein thrombosis: etiology, clinical presentation and management

    by Sadeer Alzubaidi, Indravadan Patel, Aman Saini, Grace Knuttinen, Sailendra Naidu, Scott Kriegshuaser, Hassan Albadawi, Rahmi Oklu

    The aim of this article is to focus on etiology, risk factors, clinical presentation and classification systems of acute and chronic PVT as well as focusing on current diagnostic and therapeutic options for the management of acute and chronic PVT. PVT represents a serious clinical concern in cirrhotic patients and in those with specific local or systemic risk factors. The rate and extent of thrombus formation can significantly impact patient presentation and the resulting clinical outcomes. The presentation of acute PVT can range from abdominal pain to intestinal ischemia/infarction and even death, while chronic PVT can remain clinically silent. A number of imaging modalities including US, CT and MRI can be used to confirm the diagnosis. In addition to addressing underlying risk factors, AC therapy forms a cornerstone of treatment and has demonstrated efficacy in both acute and chronic settings. Proper caution should be used when initiating AC therapy in cirrhotic patients given their underlying coagulopathic status with attention now being paid to NOACs and LMWH. For patients with bowel ischemia, extensive thrombosis, contraindications or poor response to AC, or for those with co-morbidities that preclude AC, minimally invasive endovascular techniques offer alternative treatment options. Familiarity with the etiology, clinical presentation and classification of PVT optimize early detection and incorporate effective therapeutic options, the management of these complex patients should be undertaken by a multidisciplinary team. Minimally invasive catheter-based therapies and endovascular portosystemic shunt creation demonstrated efficacy in the treatment of AC-resistant patients and for patients with extensive or complicated disease.